Patient with bipolar disorder and familial QT prolongation: What to do?

Journal of Psychiatric Practice

Volumn 12, Issue 2, 2006, Pages 109-112

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; ARIPIPRAZOLE; ATENOLOL; ATOMOXETINE; BENZATROPINE; CLONAZEPAM; CYTOCHROME P450 INHIBITOR; DEXMETHYLPHENIDATE; FEXOFENADINE; FLUOXETINE; KETOCONAZOLE; NEUROLEPTIC AGENT; QUETIAPINE; TERFENADINE; THIORIDAZINE; VALPROIC ACID; ZIPRASIDONE; TRANQUILIZER;

ADOLESCENT; AGITATION; AKATHISIA; ANAMNESIS; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CASE REPORT; CONGENITAL DEAFNESS; DEPRESSION; DRUG ABSORPTION; DRUG FATALITY; DRUG INHIBITION; DRUG SAFETY; DRUG WITHDRAWAL; EUPHORIA; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; HUMAN; HYPOMANIA; POTASSIUM CURRENT; QT PROLONGATION; RESTLESSNESS; SUDDEN DEATH; TREMOR; CHEMICALLY INDUCED DISORDER; ELECTROCARDIOGRAPHY; GENETICS; HOSPITALIZATION; LONG QT SYNDROME;

ADOLESCENT; ANTIMANIC AGENTS; BIPOLAR DISORDER; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; SEVERITY OF ILLNESS INDEX;

EID: 33745623718     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200603000-00006     Document Type: Article

References (37)

1. De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: A call for consensus. Eur J Clin Pharmacol 2001;57:185-209.
2. Morganroth J. Relations of QTc prolongation on the electrocardiogram to Torsades de Pointes: Definitions and mechanisms. Am J Cardiol 1993;72:10B-13B.
3. Krähenbühl S, Sauter B, Kupferschmidt H, et al. Case report: Reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am J Med Sci 1995;309:315-6.
4. Tamargo J. Drug-induced torsades de pointes: From molecular biology to bedside. Jpn J Pharmacol 2000;83:1-19.
5. Antzelevitch C, Escande D, Lacerda A, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs. Eur Heart J 2001;22(Suppl K):K2-K120.
6. Sanguinetti MC, Jiang C, Curran ME. A mechanistic link between ian inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
7. Preskorn SH. The human genome project and drug discovery in psychiatry: Identifying novel targets. J Psych Prac 2001;7:133-40.
8. Preskorn SH. The human genome project and modern drug development in psychiatry. J Psych Prac 2000;6:272-6.
9. Preskorn SH. Antipsychotic drug development in the pre-human-genome era: A full circle. J Psych Prac 2001;7:209-13.
10. Preskorn SH. Drug discovery in psychiatry: Drilling down on the target of interest. J Psych Prac 2001;7:267-72.
11. Drici M-D, Wang W, Liu X-K, et al. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharm 1998;18:477-81.
12. Drolet B, Vincent F, Rail J, et al. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharm Exp Ther 1999;288:1261-8.
13. Furberg C, Hornell H. Familial QT prolongation and risk of sudden death. Acta Paediatr Scand 1975;64:777-82.
14. Flockhart DA. Drug interactions, cardiac toxicity, and terfenadine: From bench to clinic? J Clin Psychopharmacol 1996;16:101-3.
15. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
16. Honig PK, Wortham DC, Lazarev A, et al. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996;36:345-51.
17. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-8.
18. Honig PK, Wortham DC, Hull R, et al. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993;33:1201-6.
19. Mathews DR. Torsades de pointes occurring in association with terfenadine use. JAMA 1991;266:2375-6.
20. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993;21:403-9.
21. von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996;16:104-12.
22. Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clin Pharmacol Ther 1999;66:461-71.
23. Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
24. Mathews DR. Torsades de pointes occurring in association with terfenadine use. JAMA 1991;266:2375-6.
25. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-90.
26. Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
27. Zimmerman M, Duruz H, Guinand O, et al. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992;13:1002-3.
28. Carlson A, Morris L. Coprescription of terfenadine and erythromycin or ketaconazole: An assessment of potential harm: Pharmacists can be key in changing prescribing behavior to avoid drug-drug interactions. Science & Practice 1996;NS36:263-9.
29. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety 2000;23:215-28.
30. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: Implications for drug approval and labeling. Drug Safety 2001;24:323-51.
31. Harvekamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Eur Heart J 2000;21:1216-31.
32. Beelen AP, Yeo KT, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001;20:215-9.
33. Cutler NR, Sramek J. Atypical antipsychotics and QT prolongation: A class effect. Current Opinion in CPNS Investigational Drugs 2000;2:52-7.
34. Glassman AH, Bigger JT Jr. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82.
35. Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: Low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 2002;300:64-71.
36. Reilly JG, Ayis SA, Ferrier IN, et al. Thioridazine and sudden death in psychiatric in-patients. Br J Psychiatry 2002;180:515-22.
37. FDA Pharmacological Drugs Advisory Committe. Pfizer briefing document for ziprasidone mesylate for intramuscular injection. Feb. 15, 2001. (www.fda.gov/ohrms/dockets/ac/01/briefing/3685b2_01_pfizer.pdf, accessed Mar 6, 2006.)